Craig Mayer, Nick WIlliams, Vojtech Huser
Lister Hill National Center for Biomedical Communications, National Library of Medicine, NIH, Bethesda, MD

See the full regCTG repository at https://github.com/lhncbc/CRI/tree/master/regCTG

To return to the list of conditions and view other reports go to https://lhncbc.github.io/CRI/regCTG/regCTG-condition_report_links.html


Study Counts

Type Study_count
Total_Studies 147
interventional 109
Observational 37
Registry 1

Studies over Time by Start Date

```

Interventional Trials

Intervention Type

intervention_type Study_Count
Drug 39
Drug|placebo 37
Other 12
Behavioral 7
Device 3
Biological 2
Radiation 2
Behavioral|Other 1
Biological|placebo 1
Dietary Supplement 1
Dietary Supplement|placebo 1
Genetic|Other|Procedure 1
Genetic|Procedure 1
Procedure 1

Count of Studies by Intervention (normalized and mapped)

Interventions over Time

Yearly studies for each intervention by start date

Studies by Country

Country Study_Count
United States 44
France 11
Germany 6
United Kingdom 6
United States|Canada 5
NA 4
Canada 3
Spain 3
Australia|Canada|Denmark|France|Germany|Poland|United Kingdom 2
Brazil 2
Canada|Germany|United Kingdom 2
Denmark|Netherlands|Norway|Sweden 2
United States|Australia|Canada 2
Austria|Belgium|France|Germany|Italy|Portugal|Spain|United Kingdom 1
Austria|France|Germany|Switzerland 1
China 1
France|Netherlands 1
Korea, Republic of 1
Netherlands 1
Netherlands|United Kingdom 1
Switzerland 1
United States|Argentina|Australia|Austria|Canada|Chile|Denmark|France|Germany|Italy|Japan|Netherlands|New Zealand|Poland|Russian Federation|Spain|Switzerland|United Kingdom 1
United States|Australia 1
United States|Australia|Austria|Canada|Denmark|France|Germany|Italy|Netherlands|Poland|Russian Federation|United Kingdom 1
United States|Australia|Canada|Denmark|Germany|Sweden|United Kingdom 1
United States|Canada|Czechia|Germany|Italy|Netherlands|Portugal|Russian Federation|Spain|United Kingdom 1
United States|Canada|Germany|Netherlands|Spain|United Kingdom 1
United States|Canada|Germany|Poland|United Kingdom 1
United States|Canada|Germany|United Kingdom 1
United States|Germany|Spain 1

Sites per Study

Site_count Study_Count
1 67
2 7
3 3
4 2
6 2
7 2
8 2
9 2
12 3
13 1
15 1
19 2
20 2
22 1
28 1
31 1
32 1
37 1
38 2
41 1
43 1
53 1
57 1
58 1
101 1

Phase

Phase Study_Count
Phase 2 32
Phase 1 28
N/A 22
Phase 3 13
Phase 1/Phase 2 8
Early Phase 1 2
Phase 2/Phase 3 2
Phase 4 2

Number of Arms

Number_of_Arms Count_of_Studies
1 27
2 44
3 18
4 4
5 5
6 2
11 1
NA 8

Enrollment Metrics by Phase

Measure Early.Phase.1 N.A Phase.1 Phase.1.Phase.2 Phase.2 Phase.2.Phase.3 Phase.3 Phase.4
Min. 45.00 9.0000 6.00000 9.00 10.00000 114.00 22.00 2.0
1st Qu. 56.25 25.0000 11.75000 23.00 25.00000 142.25 119.75 6.5
Median 67.50 50.0000 20.00000 53.00 43.00000 170.50 240.00 11.0
Mean 67.50 105.9545 31.85714 42.75 90.78125 170.50 357.25 11.0
3rd Qu. 78.75 101.5000 38.25000 60.75 101.50000 198.75 462.00 15.5
Max. 90.00 1000.0000 100.00000 64.00 408.00000 227.00 1050.00 20.0

Trial Group Type

group_type Group_Count
Experimental 155
Placebo Comparator 34
Other 21
Active Comparator 13
NA 8
No Intervention 7
Sham Comparator 3

Intervention Model

intervention_model Study_Count
Parallel Assignment 55
Single Group Assignment 30
Crossover Assignment 17
Sequential Assignment 4
NA 3

Primary Purpose

primary_purpose Study_Count
Treatment 78
NA 9
Other 8
Basic Science 5
Diagnostic 4
Health Services Research 2
Prevention 1
Screening 1
Supportive Care 1

Observational Studies

Studies by Country

Country Study_Count
United States 19
France 5
Taiwan 2
United States|Canada 2
Austria|Belgium|Czechia|Denmark|Finland|France|Germany|Italy|Netherlands|Norway|Poland|Portugal|Russian Federation|Spain|Sweden|Switzerland|United Kingdom 1
Canada 1
Croatia|France|Germany|Slovenia 1
Germany|United Kingdom 1
Italy 1
NA 1
United States|Australia|Canada 1
United States|Australia|Canada|United Kingdom 1
United States|Canada|Germany|Italy|United Kingdom 1

Sites per Study

Site_count Study_Count
1 25
2 3
4 3
5 2
20 1
22 1
52 1
140 1

Enrollment Metrics

Measure Observational
Min 11.00
1st Qu 55.00
Median 90.00
Mean 1442.27
3rd Qu 315.00
Max 20000.00

Observation Model

observational_model Study_Count
Cohort 14
Case-Control 7
Other 5
NA 5
Case-Only 3
Case Control 2
Ecologic or Community 1

Time Perspective

time_perspective Study_Count
Prospective 23
Cross-Sectional 7
Retrospective 3
NA 3
Other 1

Registries

Studies by Country

Country Study_Count
United States|Argentina|Australia|Austria|Belgium|Canada|Chile|Colombia|Denmark|France|Germany|Ireland|Italy|Netherlands|New Zealand|Poland|Portugal|Spain|Switzerland|United Kingdom 1

Sites per Study

Site_count Study_Count
177 1

Enrollment Metrics

Measure Registries
Min 20000
1st Qu 20000
Median 20000
Mean 20000
3rd Qu 20000
Max 20000

Registry Model

observational_model Study_Count
Other 1

Time Perspective

time_perspective Study_Count
Prospective 1

Follow-up

target_duration Study_Count
1 Year 1

Overview of Studies

Interventional Trials

#If less then 500 trials

nct_id brief_title link overall_status source primary_completion_date
NCT04000594 A Study to Investigate the Pharmacokinetics and Pharmacodynamics of RO7234292 (RG6042) in CSF and Plasma, and Safety and Tolerability Following Intrathecal Administration in Patients With Huntington’s Disease https://ClinicalTrials.gov/show/NCT04000594 Recruiting Hoffmann-La Roche 2021-02-17
NCT04102579 Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Chorea Associated With Huntington Disease https://ClinicalTrials.gov/show/NCT04102579 Recruiting Neurocrine Biosciences 2021-03-31
NCT03344601 PHysical Activity and Exercise Outcomes in Huntington’s Disease https://ClinicalTrials.gov/show/NCT03344601 Active, not recruiting Cardiff University 2020-04-30
NCT03342053 A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7234292 (ISIS 443139) in Huntington’s Disease Patients Who Participated in Prior Investigational Studies of RO7234292 (ISIS 443139) https://ClinicalTrials.gov/show/NCT03342053 Completed Hoffmann-La Roche 2019-10-08
NCT03306888 Feasibility and Acceptability of Implementing a Clinic-based Physical Activity Coaching Intervention in People With Premanifest and Early Stage HD https://ClinicalTrials.gov/show/NCT03306888 Completed Teachers College, Columbia University 2019-04-01
NCT03252535 Dose-response Evaluation of the Cellavita HD Product in Patients With Huntington’s Disease https://ClinicalTrials.gov/show/NCT03252535 Active, not recruiting Azidus Brasil 2022-01-31
NCT03233646 OCTA in Mild Cognitive Impairment and Alzheimer’s Disease https://ClinicalTrials.gov/show/NCT03233646 Recruiting Duke University 2021-04-01
NCT03225846 Safety and Tolerability of WVE-120102 in Patients With Huntington’s Disease https://ClinicalTrials.gov/show/NCT03225846 Recruiting Wave Life Sciences Ltd. 2020-12-31
NCT03225833 Safety and Tolerability of WVE-120101 in Patients With Huntington’s Disease https://ClinicalTrials.gov/show/NCT03225833 Recruiting Wave Life Sciences Ltd. 2020-12-31
NCT03193099 Decoding Presymptomatic White Matter Changes in Huntington Disease https://ClinicalTrials.gov/show/NCT03193099 Completed Institut National de la Santé Et de la Recherche Médicale, France 2019-12-30
NCT03019289 A Study to Evaluate Sigma-1 and Dopamine-2 Receptor Occupancy by Pridopidine in the Human Brain of Healthy Volunteers and in Patients With Huntington’s Disease https://ClinicalTrials.gov/show/NCT03019289 Completed Prilenia 2018-02-09
NCT02990676 Exploring Computerised Cognitive Training for People With Huntington’s Disease https://ClinicalTrials.gov/show/NCT02990676 Completed Cardiff University 2019-03-13
NCT02956148 Follow-up Measurement of Brain PDE10A Enzyme Levels in Huntington´s Disease Gene Expansion Carriers https://ClinicalTrials.gov/show/NCT02956148 Completed CHDI Foundation, Inc. 2017-10-05
NCT02926820 Working Memory Training in Huntington’s Disease https://ClinicalTrials.gov/show/NCT02926820 Completed York University 2016-03-31
NCT02876445 Caregiver Burden in Huntington’s Disease https://ClinicalTrials.gov/show/NCT02876445 Completed Assistance Publique - Hôpitaux de Paris 2016-03-31
NCT02750982 Laughter Therapy Effects on Mood, Stress and Self-efficacy in People With Neurological Diseases. https://ClinicalTrials.gov/show/NCT02750982 Completed Brown, Theodore R., M.D., MPH 2018-08-31
NCT02728115 Safety Evaluation of Cellavita HD Administered Intravenously in Participants With Huntington’s Disease https://ClinicalTrials.gov/show/NCT02728115 Active, not recruiting Azidus Brasil 2022-10-31
NCT02535884 Deep Brain Stimulation (DBS) of the Globus Pallidus (GP) in Huntington’s Disease (HD) https://ClinicalTrials.gov/show/NCT02535884 Recruiting Heinrich-Heine University, Duesseldorf 2020-06-30
NCT02519036 Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 443139 in Participants With Early Manifest Huntington’s Disease https://ClinicalTrials.gov/show/NCT02519036 Completed Ionis Pharmaceuticals, Inc. 2017-11-08
NCT02509793 A Pilot Study Assessing Impulsivity in Patients With Huntington’s Disease on Xenazine (Tetrabenazine) https://ClinicalTrials.gov/show/NCT02509793 Recruiting The Methodist Hospital System 2023-07-01
NCT02481674 A Study in Subjects With Late Prodromal and Early Manifest Huntington’s Disease (HD) to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of Pepinemab (VX15/2503) https://ClinicalTrials.gov/show/NCT02481674 Active, not recruiting Vaccinex Inc. 2020-05-31
NCT02464293 A Pilot Evaluation of Mindfulness-based Cognitive Therapy for People With Huntington’s Disease https://ClinicalTrials.gov/show/NCT02464293 Completed Lancaster University 2018-01-31
NCT02453061 A Comparative Phase 2 Study Assessing the Efficacy of Triheptanoin, an Anaplerotic Therapy in Huntington’s Disease https://ClinicalTrials.gov/show/NCT02453061 Active, not recruiting Institut National de la Santé Et de la Recherche Médicale, France 2019-12-31
NCT02336633 Resveratrol and Huntington Disease https://ClinicalTrials.gov/show/NCT02336633 Completed Assistance Publique - Hôpitaux de Paris 2019-10-31
NCT02268617 Treadmill Walking in Individuals With Dementia With Lewy Bodies and Huntington’s Disease https://ClinicalTrials.gov/show/NCT02268617 Completed Ohio State University 2016-08-31
NCT02252380 ExAblate Transcranial MRgFUS for the Management of Treatment-Refractory Movement Disorders https://ClinicalTrials.gov/show/NCT02252380 Active, not recruiting InSightec 2021-12-31
NCT02216474 Brain Stimulation in Movement Disorders https://ClinicalTrials.gov/show/NCT02216474 Completed Birmingham and Solihull Mental Health NHS Foundation Trust 2018-09-30
NCT02215616 A Clinical Study in Participants With Huntington’s Disease (HD) to Assess Efficacy and Safety of Three Oral Doses of Laquinimod https://ClinicalTrials.gov/show/NCT02215616 Completed Teva Pharmaceutical Industries 2018-06-19
NCT02208934 Study To Assess the Safety and Tolerability of Single Ascending Oral Doses of PBF-999 in Healthy Young Male Volunteers https://ClinicalTrials.gov/show/NCT02208934 Completed Fundació Institut de Recerca de l’Hospital de la Santa Creu i Sant Pau 2015-10-31
NCT02197130 Randomized, Placebo Controlled Study Of The Efficacy And Safety Of PF-02545920 In Subjects With Huntington’s Disease https://ClinicalTrials.gov/show/NCT02197130 Completed Pfizer 2016-09-30
NCT02061722 [PETDE10] Imaging of PDE10A Enzyme Levels in Huntington’s Disease Gene Expansion Carriers and Healthy Controls With PET. https://ClinicalTrials.gov/show/NCT02061722 Completed CHDI Foundation, Inc. 2016-05-31
NCT01306929 Open-label Extension Study of Pridopidine (ACR16) in the Symptomatic Treatment of Huntington Disease https://ClinicalTrials.gov/show/NCT01306929 Completed Prilenia 2018-01-05
NCT02006472 A Phase 2, to Evaluating the Safety and Efficacy of Pridopidine Versus Placebo for Symptomatic Treatment in Patients With Huntington’s Disease https://ClinicalTrials.gov/show/NCT02006472 Completed Prilenia 2016-07-31
NCT01914965 Apathy Cure Through Bupropion in Huntington’s Disease https://ClinicalTrials.gov/show/NCT01914965 Completed Charite University, Berlin, Germany 2014-05-31
NCT01897896 Alternatives for Reducing Chorea in Huntington Disease https://ClinicalTrials.gov/show/NCT01897896 Completed Teva Pharmaceutical Industries 2017-08-21
NCT01879267 Exercise Effects in Huntington’s Disease https://ClinicalTrials.gov/show/NCT01879267 Completed University of Zurich 2018-01-31
NCT01842919 Dance and Huntington Disease https://ClinicalTrials.gov/show/NCT01842919 Completed Institut National de la Santé Et de la Recherche Médicale, France 2015-07-28
NCT01834911 Effect of Tetrabenazine on Stroop Interference in HD https://ClinicalTrials.gov/show/NCT01834911 Completed New York Medical College 2018-01-01
NCT01806896 Study Evaluating The Safety, Tolerability And Brain Function Of 2 Doses Of PF-0254920 In Subjects With Early Huntington’s Disease https://ClinicalTrials.gov/show/NCT01806896 Completed Pfizer 2015-01-31
NCT01795859 First Time Use of SD-809 in Huntington Disease https://ClinicalTrials.gov/show/NCT01795859 Completed Teva Pharmaceutical Industries 2014-12-05
NCT01735981 The Effect of Video Game Exercise on Dynamic Balance and Gait in Individuals With Huntington’s Disease https://ClinicalTrials.gov/show/NCT01735981 Completed Ohio State University 2010-11-30
NCT01696708 Utilization of 31P-Nuclear Magnetic Resonance Spectroscopy to Monitor Brain Energy Deficit in Huntington Disease https://ClinicalTrials.gov/show/NCT01696708 Completed Institut National de la Santé Et de la Recherche Médicale, France 2015-11-30
NCT01602900 Healthy Volunteer Positron Emission Tomography (PET) Brain Occupancy Study of a Phosphodiesterase 4 (PDE4) Inhibitor in Huntington’s Disease https://ClinicalTrials.gov/show/NCT01602900 Completed GlaxoSmithKline 2012-04-12
NCT01590888 Effect of PBT2 in Patients With Early to Mid Stage Huntington Disease https://ClinicalTrials.gov/show/NCT01590888 Completed Prana Biotechnology Limited 2013-07-31
NCT01573819 A Repeat Dose Study in Healthy Volunteers Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK356278 https://ClinicalTrials.gov/show/NCT01573819 Completed GlaxoSmithKline 2012-04-02
NCT01521832 Escalating Dose Study in Healthy Volunteers With SEN0014196 https://ClinicalTrials.gov/show/NCT01521832 Completed Siena Biotech S.p.A. 2010-05-31
NCT01521585 A Phase II Safety and Tolerability Study With SEN0014196 https://ClinicalTrials.gov/show/NCT01521585 Completed Siena Biotech S.p.A. 2012-10-31
NCT01502046 Neuroprotection by Cannabinoids in Huntington’s Disease https://ClinicalTrials.gov/show/NCT01502046 Completed Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal 2012-06-30
NCT01485965 A Open-label Food Effect Study With SEN0014196 in Subjects With Huntington Disease https://ClinicalTrials.gov/show/NCT01485965 Completed Siena Biotech S.p.A. 2012-11-30
NCT01485952 An Exploratory Clinical Trial in Early Stage Huntington’s Disease Patients With SEN0014196 https://ClinicalTrials.gov/show/NCT01485952 Completed Siena Biotech S.p.A. 2011-11-30
NCT01458470 A Trial of Memantine as Symptomatic Treatment for Early Huntington Disease https://ClinicalTrials.gov/show/NCT01458470 Completed University of British Columbia 2012-08-31
NCT01412151 Creatine Safety & Tolerability in Huntington’s Disease https://ClinicalTrials.gov/show/NCT01412151 Completed Massachusetts General Hospital 2011-11-30
NCT01411163 Premanifest Huntington’s Disease Extension Study II: Creatine Safety & Tolerability https://ClinicalTrials.gov/show/NCT01411163 Completed Massachusetts General Hospital 2013-05-31
NCT01411150 Premanifest Huntington’s Disease: Creatine Safety & Tolerability Extension Study https://ClinicalTrials.gov/show/NCT01411150 Completed Massachusetts General Hospital 2012-09-30
NCT01359774 31P-MRS and Huntington Disease https://ClinicalTrials.gov/show/NCT01359774 Completed Institut National de la Santé Et de la Recherche Médicale, France 2012-04-30
NCT01357681 Effects of EGCG (Epigallocatechin Gallate) in Huntington’s Disease (ETON-Study) https://ClinicalTrials.gov/show/NCT01357681 Completed Charite University, Berlin, Germany 2015-05-31
NCT01339130 Assessment of Social-emotional Functioning in Neurological Diseases https://ClinicalTrials.gov/show/NCT01339130 Completed Centre Hospitalier Universitaire, Amiens 2013-06-30
NCT04400331 Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated With Huntington Disease https://ClinicalTrials.gov/show/NCT04400331 Enrolling by invitation Neurocrine Biosciences 2023-07-31
NCT04120493 Safety and Proof-of-Concept (POC) Study With AMT-130 in Adults With Early Manifest Huntington Disease https://ClinicalTrials.gov/show/NCT04120493 Recruiting UniQure Biopharma B.V. 2022-12-31
NCT04071639 Symptomatic Therapy for Patients With Huntington’s Disease https://ClinicalTrials.gov/show/NCT04071639 Recruiting Second Affiliated Hospital, School of Medicine, Zhejiang University 2024-12-31
NCT04012411 Study of BDNF Pathway Biomarkers in the Cerebrospinal Fluid in Patients With Huntington’s Disease https://ClinicalTrials.gov/show/NCT04012411 Recruiting University Hospital, Montpellier 2022-07-31
NCT03980938 Within Subject Crossover Study of Cognitive Effects of Neflamapimod in Early-Stage Huntington Disease https://ClinicalTrials.gov/show/NCT03980938 Recruiting EIP Pharma Inc 2020-06-30
NCT03854019 Evaluating the Efficacy of Dextromethorphan/Quinidine in Treating Irritability in Huntington’s Disease https://ClinicalTrials.gov/show/NCT03854019 Recruiting The University of Texas Health Science Center, Houston 2019-11-01
NCT03842969 An Open-Label Extension Study to Evaluate Long-Term Safety and Tolerability of RO7234292 (RG6042) in Huntington’s Disease Patients Who Participated in Prior Roche and Genentech Sponsored Studies https://ClinicalTrials.gov/show/NCT03842969 Recruiting Hoffmann-La Roche 2024-06-19
NCT03787758 A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of SAGE-718 Oral Solution in Patients With Huntington’s Disease - Part B https://ClinicalTrials.gov/show/NCT03787758 Completed Sage Therapeutics 2019-10-07
NCT02418546 Electronic-health Application To Measure Outcomes REmotely Clinical Trial https://ClinicalTrials.gov/show/NCT02418546 Completed Massachusetts General Hospital 2017-12-31
NCT03764215 Nilotinib in Huntington’s Disease https://ClinicalTrials.gov/show/NCT03764215 Recruiting Georgetown University 2020-11-30
NCT03761849 A Study to Evaluate the Efficacy and Safety of Intrathecally Administered RO7234292 (RG6042) in Patients With Manifest Huntington’s Disease https://ClinicalTrials.gov/show/NCT03761849 Recruiting Hoffmann-La Roche 2022-03-01
NCT03713892 CKD-504 in SAD and MAD in Healthy Korean and Caucasian Adult Male and Female Subjects https://ClinicalTrials.gov/show/NCT03713892 Recruiting Chong Kun Dang Pharmaceutical 2020-12-31
NCT03664804 Study to Measure Cerebrospinal Fluid Mutant Huntingtin Protein in Participants With Early Manifest Stage I or Stage II Huntington’s Disease https://ClinicalTrials.gov/show/NCT03664804 Active, not recruiting Hoffmann-La Roche 2020-09-03
NCT03575676 Efficacy and Safety of SOM3355 in Huntington’s Disease Chorea https://ClinicalTrials.gov/show/NCT03575676 Completed SOM Biotech SL 2019-08-22
NCT03515213 Safety and Efficacy of Fenofibrate as a Treatment for Huntington’s Disease https://ClinicalTrials.gov/show/NCT03515213 Active, not recruiting University of California, Irvine 2019-12-31
NCT03417583 Assessing Efficacy of Neuropsychiatric Assessment and Treatment Protocols in Huntington’s Disease Patients https://ClinicalTrials.gov/show/NCT03417583 Recruiting Vanderbilt University Medical Center 2021-12-31
NCT00990613 A Study Evaluating The Absorption Of Dimebon Into The Body From A Dimebon Solution Applied To The Skin https://ClinicalTrials.gov/show/NCT00990613 Completed Pfizer 2010-01-31
NCT00988624 A Study In Healthy Volunteers To Estimate The Pharmacokinetics Of Four Modified-Release Formulations Of Dimebon (Latrepirdine) https://ClinicalTrials.gov/show/NCT00988624 Completed Pfizer 2009-12-31
NCT00980694 Bioavailability of Ubiquinol in Huntington Disease https://ClinicalTrials.gov/show/NCT00980694 Completed University of Rochester 2012-07-31
NCT00975481 A Study To Evaluate The Abuse Potential Of Single Oral Doses Of Dimebon (Latrepirdine) In Healthy Recreational Polydrug Users https://ClinicalTrials.gov/show/NCT00975481 Completed Pfizer 2010-02-28
NCT00970229 Evaluation of [123I]MNI-420 and SPECT as a Marker of the Adenosine A2a Receptor in PD, HD and Healthy Subjects. https://ClinicalTrials.gov/show/NCT00970229 Completed Institute for Neurodegenerative Disorders 2015-04-30
NCT00931073 A Phase I Study To Estimate The Effect Of Ketoconazole And Omeprazole On The Pharmacokinetics Of Dimebon In Healthy Subjects Who Are Normal Or Poor CYP2D6 Metabolizers https://ClinicalTrials.gov/show/NCT00931073 Completed Pfizer 2009-10-31
NCT00920946 A Safety and Efficacy Study of Dimebon in Patients With Huntington Disease https://ClinicalTrials.gov/show/NCT00920946 Completed Medivation, Inc. 2011-07-31
NCT00920699 Study in PRE-manifest Huntington’s Disease of Coenzyme Q10 (UbiquinonE) Leading to Preventive Trials (PREQUEL) https://ClinicalTrials.gov/show/NCT00920699 Completed Johns Hopkins University 2012-03-31
NCT00902889 Deep Brain Stimulation of the Globus Pallidus in Huntington’s Disease https://ClinicalTrials.gov/show/NCT00902889 Completed Heinrich-Heine University, Duesseldorf 2012-04-30
NCT00870974 A PET Brain Imaging Study of mGluR5 in Subjects With Neuropsychiatric Conditions https://ClinicalTrials.gov/show/NCT00870974 Completed Institute for Neurodegenerative Disorders 2016-10-31
NCT00831506 Dimebon (PF-01913539)-Digoxin Drug-Drug Interaction Study In Healthy Subjects https://ClinicalTrials.gov/show/NCT00831506 Completed Pfizer 2009-05-31
NCT00827034 A Phase 1, Randomized, Open-Label, Two-Way Crossover Study To Evaluate The Steady-State Effect Of Dimebon (PF 01913539) On The Single-Dose Pharmacokinetics And Pharmacodynamics Of Warfarin In Healthy Subjects https://ClinicalTrials.gov/show/NCT00827034 Completed Pfizer 2009-04-30
NCT00825084 A Phase 1 Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [PF-01913539] In Japanese And Western Healthy Subjects https://ClinicalTrials.gov/show/NCT00825084 Completed Pfizer 2009-05-31
NCT00824590 A Phase 1, Non-Randomized, Open-Label, Single-Dose Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [PF 01913539] In Subjects With Severely-Impaired And Normal Renal Function https://ClinicalTrials.gov/show/NCT00824590 Completed Pfizer 2009-10-31
NCT01882062 Proof of Concept of an Anaplerotic Study Using Brain Phosphorus Magnetic Resonance Spectroscopy in Huntington Disease https://ClinicalTrials.gov/show/NCT01882062 Completed Institut National de la Santé Et de la Recherche Médicale, France 2013-07-31
NCT02507284 Tolerability, Safety, and Activity of SRX246 in Irritable Subjects With Huntington’s Disease https://ClinicalTrials.gov/show/NCT02507284 Completed Azevan Pharmaceuticals 2018-09-10
NCT00788047 A Phase 1 Study To Evaluate The Effect Of Dimebon On The Pharmacokinetics Of Dextromethorphan https://ClinicalTrials.gov/show/NCT00788047 Completed Pfizer 2009-01-31
NCT00724048 A Study of Pridopidine (ACR16) for the Treatment of Patients With Huntington’s Disease https://ClinicalTrials.gov/show/NCT00724048 Completed Teva Pharmaceutical Industries 2011-06-30
NCT00665223 A Study of Treatment With Pridopidine (ACR16) in Patients With Huntington’s Disease https://ClinicalTrials.gov/show/NCT00665223 Completed Teva Pharmaceutical Industries 2011-06-30
NCT00632645 Neuroleptic and Huntington Disease Comparison of : Olanzapine, la Tetrabenazine and Tiapride https://ClinicalTrials.gov/show/NCT00632645 Completed Assistance Publique - Hôpitaux de Paris 2017-04-28
NCT00592995 Creatine Safety and Tolerability in Premanifest HD: PRECREST https://ClinicalTrials.gov/show/NCT00592995 Completed Massachusetts General Hospital 2012-09-30
NCT00497159 A Study of the Novel Drug Dimebon in Patients With Huntington’s Disease https://ClinicalTrials.gov/show/NCT00497159 Completed Medivation, Inc. 2008-06-30
NCT00387270 Safety Study of the Novel Drug Dimebon to Treat Patients With Huntington’s Disease https://ClinicalTrials.gov/show/NCT00387270 Completed Medivation, Inc. 2007-03-31
NCT00368849 Atomoxetine and Huntington’s Disease https://ClinicalTrials.gov/show/NCT00368849 Completed University of Iowa 2008-02-29
NCT00277602 Riluzole in Huntington’s Disease https://ClinicalTrials.gov/show/NCT00277602 Completed Sanofi 2004-07-31
NCT00277355 Pilot Study of Minocycline in Huntington’s Disease https://ClinicalTrials.gov/show/NCT00277355 Completed Huntington Study Group 2008-10-31
NCT00271596 Citalopram to Enhance Cognition in HD https://ClinicalTrials.gov/show/NCT00271596 Completed University of Iowa 2011-04-30
NCT00219804 Efficacy and Safety of Tetrabenazine in Chorea https://ClinicalTrials.gov/show/NCT00219804 Completed Prestwick Pharmaceuticals NA
NCT00212316 Safety and Tolerability Study of Phenylbutyrate in Huntington’s Disease (PHEND-HD) https://ClinicalTrials.gov/show/NCT00212316 Completed University of Rochester NA
NCT00190450 MIG-HD: Multicentric Intracerebral Grafting in Huntington’s Disease https://ClinicalTrials.gov/show/NCT00190450 Completed Assistance Publique - Hôpitaux de Paris 2013-12-31
NCT00178360 Effects of Music Therapy on Huntington’s Disease https://ClinicalTrials.gov/show/NCT00178360 Completed University of Rochester 2008-12-31
NCT00146211 TREND-HD - A Trial of Ethyl-EPA (Miraxionâ„¢) in Treating Mild to Moderate Huntington’s Disease https://ClinicalTrials.gov/show/NCT00146211 Completed Amarin Neuroscience Ltd 2007-08-31
NCT00095355 Effects of Lithium and Divalproex`on Brain-Derived Neurotrophic Factor in Huntington’s Disease https://ClinicalTrials.gov/show/NCT00095355 Completed National Institutes of Health Clinical Center (CC) NA
NCT00001930 Treatment of Huntington’s Chorea With Amantadine https://ClinicalTrials.gov/show/NCT00001930 Completed National Institutes of Health Clinical Center (CC) NA
NCT00029874 Minocycline in Patients With Huntington’s Disease https://ClinicalTrials.gov/show/NCT00029874 Completed FDA Office of Orphan Products Development NA
NCT00026988 Creatine Therapy for Huntington’s Disease https://ClinicalTrials.gov/show/NCT00026988 Completed National Center for Complementary and Integrative Health (NCCIH) NA

Observational Studiess

#If less then 500 studies

nct_id brief_title link overall_status source primary_completion_date
NCT03034122 Is Caffeine an Environmental Modifier in Huntington’s Disease? https://ClinicalTrials.gov/show/NCT03034122 Recruiting University Hospital, Lille 2021-10-31
NCT02994719 Gait Analysis in Neurological Disease https://ClinicalTrials.gov/show/NCT02994719 Active, not recruiting Beth Israel Deaconess Medical Center 2021-06-20
NCT02881931 FuRST 2.0 Cognitive Pre-Testing https://ClinicalTrials.gov/show/NCT02881931 Completed CHDI Foundation, Inc. 2017-07-28
NCT02855476 HDClarity: a Multi-site Cerebrospinal Fluid Collection Initiative to Facilitate Therapeutic Development for Huntington’s Disease https://ClinicalTrials.gov/show/NCT02855476 Recruiting University College, London 2021-04-01
NCT02814201 Study of Motor Slowing in Parkinson’s Disease by a Computerized Mental Chronometry Paradigm https://ClinicalTrials.gov/show/NCT02814201 Completed Centre Hospitalier Universitaire, Amiens 2016-11-30
NCT02727270 Measuring Cortisol Levels in Persons With Parkinson’s (PD) https://ClinicalTrials.gov/show/NCT02727270 Recruiting Oregon Health and Science University 2020-12-31
NCT02639871 Dynamic Neuroimaging Biomarkers in Huntington’s Disease https://ClinicalTrials.gov/show/NCT02639871 Completed Assistance Publique - Hôpitaux de Paris 2019-06-24
NCT01290861 Cognitive Assessment Battery (CAB) Beta Study https://ClinicalTrials.gov/show/NCT01290861 Completed CHDI Foundation, Inc. NA
NCT01937923 A Pre-Cellular Therapy Observational Study in Early Huntington’s Disease https://ClinicalTrials.gov/show/NCT01937923 Completed University of California, Davis 2016-07-31
NCT01931644 At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions https://ClinicalTrials.gov/show/NCT01931644 Recruiting Sanguine Biosciences 2025-08-31
NCT01919034 Evaluating the Relationship of Morphine Consumption and Pain-related Molecules in Hepatic Surgical Patients https://ClinicalTrials.gov/show/NCT01919034 Completed National Cheng-Kung University Hospital 2012-12-31
NCT01884181 Accelerated Diffusion MRI for Diagnosis of Hungtington Disease https://ClinicalTrials.gov/show/NCT01884181 Completed Chang Gung Memorial Hospital 2017-12-31
NCT01860339 Child to Adult Neurodevelopment in Gene Expanded Huntington’s Disease https://ClinicalTrials.gov/show/NCT01860339 Recruiting University of Iowa 2024-08-31
NCT01592552 A Biospecimen and Clinical Data Study on Patients With Alzheimer’s, Multiple Sclerosis, Parkinson’s, and Huntington’s, for Drug & Biomarker Discovery https://ClinicalTrials.gov/show/NCT01592552 Completed Sanguine Biosciences 2015-03-31
NCT01590602 REGISTRY-JHD - an Observational Study of the European Huntington’s Disease Network (EHDN) https://ClinicalTrials.gov/show/NCT01590602 Completed European Huntington’s Disease Network 2017-06-30
NCT01590589 REGISTRY - an Observational Study of the European Huntington’s Disease Network (EHDN) https://ClinicalTrials.gov/show/NCT01590589 Completed European Huntington’s Disease Network 2017-06-30
NCT01451463 Impact of Xenazine(Tetrabenazine)on Gait and Functional Activity in Individuals With Huntington’s Disease https://ClinicalTrials.gov/show/NCT01451463 Completed Ohio State University 2013-04-30
NCT01412125 Study of Biomarkers That Predict the Evolution of Huntington’s Disease https://ClinicalTrials.gov/show/NCT01412125 Recruiting Assistance Publique - Hôpitaux de Paris 2021-01-31
NCT04406636 Natural History Study in Huntington Disease Gene Expansion Carriers (HDGECs) - SHIELD HD https://ClinicalTrials.gov/show/NCT04406636 Recruiting Triplet Therapeutics, Inc. 2022-11-30
NCT04394767 Couple and Spouse Caregiver in Huntington’s Disease https://ClinicalTrials.gov/show/NCT04394767 Recruiting University Hospital, Lille 2021-02-28
NCT04270604 Biological Sample Collection for Research and Biobanking https://ClinicalTrials.gov/show/NCT04270604 Recruiting The New York Stem Cell Foundation 2030-01-31
NCT04257513 Clinical Study to Monitor Plasma Levels of 24OHC in Subject With HD https://ClinicalTrials.gov/show/NCT04257513 Recruiting Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta 2021-09-30
NCT04231487 Using Wearable and Mobile Data to Diagnose and Monitor Movement Disorders https://ClinicalTrials.gov/show/NCT04231487 Recruiting Rutgers, The State University of New Jersey 2021-12-31
NCT03886753 Pharmacokinetic (PK) and Pharmacodynamics (PD) Study of Ilera Specific Products https://ClinicalTrials.gov/show/NCT03886753 Active, not recruiting Children’s Hospital of Philadelphia 2020-12-31
NCT03709173 FuRST 2.0 Cognitive Pre-testing - Round 2 https://ClinicalTrials.gov/show/NCT03709173 Completed CHDI Foundation, Inc. 2019-10-25
NCT03628235 HD-Charge: Indirect and Out-of-Pocket Costs of Huntington’s Disease in the United States https://ClinicalTrials.gov/show/NCT03628235 Recruiting CHDI Foundation, Inc. 2021-12-31
NCT03599076 Wearable Sensors for Quantitative Assessment of Motor Impairment in Huntington’s Disease Huntington’s Disease https://ClinicalTrials.gov/show/NCT03599076 Recruiting BioSensics 2019-12-31
NCT03421327 Genetic Risk: Whether, When, and How to Tell Adolescents https://ClinicalTrials.gov/show/NCT03421327 Completed Johns Hopkins University 2018-12-31
NCT00491842 Individuals Patterns of Disclosure About Huntington s Disease (HD) and the Association With Adaptation to HD https://ClinicalTrials.gov/show/NCT00491842 Completed National Institutes of Health Clinical Center (CC) NA
NCT00670709 Examination of Quantitative Electroencephalographic (QEEG) Biomarkers in Huntington’s Disease https://ClinicalTrials.gov/show/NCT00670709 Completed University of California, Los Angeles 2008-02-29
NCT00654563 Memory Disorders Registry https://ClinicalTrials.gov/show/NCT00654563 Completed Cedars-Sinai Medical Center 2012-03-31
NCT00539747 Making Sense of a Positive Genetic Test Result for Huntington Disease https://ClinicalTrials.gov/show/NCT00539747 Completed National Institutes of Health Clinical Center (CC) NA
NCT00465790 Research of Biomarkers in Parkinson Disease https://ClinicalTrials.gov/show/NCT00465790 Completed Institut National de la Santé Et de la Recherche Médicale, France 2012-06-30
NCT00313495 Cooperative Huntington’s Observational Research Trial https://ClinicalTrials.gov/show/NCT00313495 Recruiting HP Therapeutics Foundation 2020-12-31
NCT00075140 Family Health After Predictive Huntington Disease (HD) Testing https://ClinicalTrials.gov/show/NCT00075140 Completed National Institute of Nursing Research (NINR) 2008-10-31
NCT00051324 Neurobiological Predictors of Huntington’s Disease (PREDICT-HD) https://ClinicalTrials.gov/show/NCT00051324 Recruiting University of Iowa 2023-03-31
NCT00004753 Long-Term Study of Cerebral Glucose Metabolism in Huntington’s Disease https://ClinicalTrials.gov/show/NCT00004753 Completed Office of Rare Diseases (ORD) NA

Registries

#If less then 500 registries

nct_id brief_title link overall_status source primary_completion_date
NCT01574053 Enroll -HD: A Prospective Registry Study in a Global Huntington’s Disease Cohort https://ClinicalTrials.gov/show/NCT01574053 Recruiting CHDI Foundation, Inc. 2062-01-31